{"id":13822,"date":"2023-09-15T22:25:00","date_gmt":"2023-09-15T14:25:00","guid":{"rendered":"https:\/\/flcube.com\/?p=13822"},"modified":"2025-01-06T18:16:04","modified_gmt":"2025-01-06T10:16:04","slug":"nona-biosciences-and-beigene-form-partnership-to-advance-antibody-discovery","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=13822","title":{"rendered":"Nona Biosciences and BeiGene Form Partnership to Advance Antibody Discovery"},"content":{"rendered":"\n

Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142<\/a>), has announced a strategic partnership with China-based BeiGene (NASDAQ: BGNE<\/a>). The collaboration focuses on the field of antibody discovery, with the aim of leveraging Nona’s proprietary technology to enhance BeiGene’s research capabilities. Financial details of the agreement have not been disclosed.<\/p>\n\n\n\n

Access to Harbour Mice HCAb Platform<\/strong>
The partnership builds upon an existing collaboration initiated in 2018, which involved the Harbour Mice H2L2 platform. Under the latest agreement, BeiGene will gain access to Nona Biosciences’ Harbour Mice HCAb platform. This platform is a significant asset in the biotech industry, offering a unique approach to antibody discovery and development.<\/p>\n\n\n\n

Implications for BeiGene and the Biotechnology Industry<\/strong>
The ability for BeiGene to utilize the Harbour Mice HCAb platform is expected to bolster the company’s antibody discovery efforts, potentially leading to the development of novel therapeutics. This collaboration highlights the growing trend of partnerships between biopharmaceutical companies to leverage cutting-edge technologies and accelerate drug discovery processes.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), has announced a strategic…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[185,2092,30,190,916,3046,128],"class_list":["post-13822","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-beigene","tag-beone-medicines","tag-biotech","tag-harbour-biomed","tag-hkg-2142","tag-nasdaq-onc","tag-nona-biosciences"],"yoast_head":"\nNona Biosciences and BeiGene Form Partnership to Advance Antibody Discovery - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), has announced a strategic partnership with China-based BeiGene (NASDAQ: BGNE). The collaboration focuses on the field of antibody discovery, with the aim of leveraging Nona's proprietary technology to enhance BeiGene's research capabilities. Financial details of the agreement have not been disclosed.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=13822\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nona Biosciences and BeiGene Form Partnership to Advance Antibody Discovery\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=13822\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-15T14:25:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-06T10:16:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13822#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13822\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Nona Biosciences and BeiGene Form Partnership to Advance Antibody Discovery\",\"datePublished\":\"2023-09-15T14:25:00+00:00\",\"dateModified\":\"2025-01-06T10:16:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13822\"},\"wordCount\":180,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"BeiGene\",\"BeOne Medicines\",\"Biotech\",\"Harbour BioMed\",\"HKG: 2142\",\"NASDAQ: ONC\",\"Nona Biosciences\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=13822#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13822\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=13822\",\"name\":\"Nona Biosciences and BeiGene Form Partnership to Advance Antibody Discovery - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-09-15T14:25:00+00:00\",\"dateModified\":\"2025-01-06T10:16:04+00:00\",\"description\":\"Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), has announced a strategic partnership with China-based BeiGene (NASDAQ: BGNE). The collaboration focuses on the field of antibody discovery, with the aim of leveraging Nona's proprietary technology to enhance BeiGene's research capabilities. Financial details of the agreement have not been disclosed.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13822#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=13822\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13822#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nona Biosciences and BeiGene Form Partnership to Advance Antibody Discovery\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Nona Biosciences and BeiGene Form Partnership to Advance Antibody Discovery - Insight, China's Pharmaceutical Industry","description":"Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), has announced a strategic partnership with China-based BeiGene (NASDAQ: BGNE). The collaboration focuses on the field of antibody discovery, with the aim of leveraging Nona's proprietary technology to enhance BeiGene's research capabilities. Financial details of the agreement have not been disclosed.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=13822","og_locale":"en_US","og_type":"article","og_title":"Nona Biosciences and BeiGene Form Partnership to Advance Antibody Discovery","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=13822","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-09-15T14:25:00+00:00","article_modified_time":"2025-01-06T10:16:04+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=13822#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=13822"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Nona Biosciences and BeiGene Form Partnership to Advance Antibody Discovery","datePublished":"2023-09-15T14:25:00+00:00","dateModified":"2025-01-06T10:16:04+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=13822"},"wordCount":180,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["BeiGene","BeOne Medicines","Biotech","Harbour BioMed","HKG: 2142","NASDAQ: ONC","Nona Biosciences"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=13822#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=13822","url":"https:\/\/flcube.com\/?p=13822","name":"Nona Biosciences and BeiGene Form Partnership to Advance Antibody Discovery - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-09-15T14:25:00+00:00","dateModified":"2025-01-06T10:16:04+00:00","description":"Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), has announced a strategic partnership with China-based BeiGene (NASDAQ: BGNE). The collaboration focuses on the field of antibody discovery, with the aim of leveraging Nona's proprietary technology to enhance BeiGene's research capabilities. Financial details of the agreement have not been disclosed.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=13822#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=13822"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=13822#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Nona Biosciences and BeiGene Form Partnership to Advance Antibody Discovery"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/13822","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=13822"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/13822\/revisions"}],"predecessor-version":[{"id":13824,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/13822\/revisions\/13824"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=13822"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=13822"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=13822"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}